According to Forbes,
The Food and Drug Administration has decided to move forward with the use of methylenedioxymethamphetamine, or MDMA after years of laboratory research on the medical uses.
Last week, the Multidisciplinary Association for Psychedelic Studies (MAPS) announced that the FDA has granted Breakthrough Therapy Designation to MDMA for the treatment of post-traumatic stress disorder (PTSD). Popularly known as a recreational drug, and as the main ingredient in ecstasy, MDMA has been shown to offer significant relief for sufferers of PTSD in clinical use trials conducted over the past several years, leading to the U.S. agency's decision.